Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK, Valeant Provide Updates On NDA For Retigabine
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (Valeant) have provided updates on the New Drug Application for retigabine. GSK and Valeant had filed a New Drug Application with the FDA
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (Valeant) have provided updates on the New Drug Application for retigabine. GSK and Valeant had filed a New Drug Application with the FDA
Schering-Plough has reported interim results from an ongoing phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor. Narlaprevir demonstrated potent antiviral activity in treatment-naive patients
Immunovaccine has entered into a master services agreement with Cato Research Canada (Cato), to assist the company in managing an upcoming Phase 1 clinical trial for DPX-0907, a
to-BBB has entered into a research collaboration with Genzyme to evaluate to-BBB’s proprietary G-Technology to safely enhance delivery of biologics for neurodegenerative diseases. G-Technology is designed to transport
Caliper Life sciences, has launched two new products that expand the LabChip GX product line: a GLP/GMP-compliant version of the operating software for the LabChip GX instrument that
Usana Health Sciences (Usana) has launched seasonal Vitamin D supplement. The supplement will be available every year from November to March. The company claimed that its supplement has
Cobra Biomanufacturing reported that the current Good Manufacturing Practice (cGMP) production of Scancell’s SCIB1 DNA vaccine has been successfully completed ahead of the planned clinical trials that are
Amylin Pharmaceuticals (Amylin) and Takeda Pharmaceutical (Takeda) have entered into a worldwide exclusive license, development and commercialisation agreement to co-develop and commercialise pharmaceutical products for the treatment of
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) reported that Benlysta (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal phase 3 trials in seropositive patients
Sosei Group (Sosei) has entered into a definitive distribution agreement with ASKA Pharmaceuticals (ASKA) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo). NorLevo is an oral